Skip to main content

Table 1 Patients' characteristics

From: Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer

Characteristics N = 56 (%)
Age
 Median years (range) 72 (48–85)
Gender
 Male/female 37 (66) / 19 (34)
Performance status
 0 / 1 / 2 24(43) / 28 (50) / 4 (7)
Smoking status
 Current / Former / Never 20(36) / 25(45) / 11 (20)
Histology
 Adeno / Sq / Non-small 25(45) / 30(54) / 1(2)
Primary tumor location
 Upper lobe or trachea / Middle or lower lobe 33(59) / 23 (41)
Clinical stage
 |||A/|||B/|||C/Others 19(34) /14(25) /10(18) /13 (23)
PD-L1 Satus
 ≥ 50% /1–49% / < 1% / unknown 9(16) /11(20) / 19(24) / 17(30)
Irradiation technique
 IMRT 28 (50)
 3D-CRT 28 (50)
Total radiotherapy dose
 60 Gy/30fr 48 (86)
 66 Gy/33fr 5 (9)
 54 Gy/27fr 1 (2)
 50 Gy/25fr 2 (4)
Chemotherapy regimen
 wCBDCA + PTX 26 (46)
 CDDP + VNR 12 (21)
 CDDP + Pemetrexed 12 (21)
 CDDP + S-1 6 (11)
Pulmonary function test
 Median %VC (range) 89.0 (53.5–124.4)
 Median %FEV1.0 (range) 80.6 (46–126)
  1. Adeno adenocarcinoma, Sq squamous cell carcinoma, PD-L1 programmes cell death -ligand 1, IMRT intensity modulated radiation therapy, 3D-CRT three dimensional-conformal radiation therapy, fr fractions, w weeekly, CBDCA carboplatin, PTX paclitaxel, CDDP cisplatin, VNR vinorelbine, VC vital capacity, FEV forced expiratory volume